WO2022056454A3 - Methods and compositions for treating hpv-positive cancers - Google Patents

Methods and compositions for treating hpv-positive cancers Download PDF

Info

Publication number
WO2022056454A3
WO2022056454A3 PCT/US2021/050227 US2021050227W WO2022056454A3 WO 2022056454 A3 WO2022056454 A3 WO 2022056454A3 US 2021050227 W US2021050227 W US 2021050227W WO 2022056454 A3 WO2022056454 A3 WO 2022056454A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
positive cancers
treating hpv
mirnas
Prior art date
Application number
PCT/US2021/050227
Other languages
French (fr)
Other versions
WO2022056454A2 (en
Inventor
Peter M. Howley
Gustavo MARTINEZ NOEL
Jennifer A. Smith
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Publication of WO2022056454A2 publication Critical patent/WO2022056454A2/en
Publication of WO2022056454A3 publication Critical patent/WO2022056454A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are methods for treating a subject who has cancer (e.g., hrHPV-positive cervical cancer), which include administering to the subject a composition that has one or more miRNAs, one or more RNAs that are processed into one or more miRNAs, or one or more DNAs that encode one or more miRNAs. Also provided are relevant compositions as well as methods for killing a cancer cell.
PCT/US2021/050227 2020-09-14 2021-09-14 Methods and compositions for treating hpv-positive cancers WO2022056454A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063078064P 2020-09-14 2020-09-14
US63/078,064 2020-09-14

Publications (2)

Publication Number Publication Date
WO2022056454A2 WO2022056454A2 (en) 2022-03-17
WO2022056454A3 true WO2022056454A3 (en) 2022-04-21

Family

ID=78086069

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/050227 WO2022056454A2 (en) 2020-09-14 2021-09-14 Methods and compositions for treating hpv-positive cancers

Country Status (1)

Country Link
WO (1) WO2022056454A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120088816A1 (en) * 2009-04-16 2012-04-12 Keio University Head-And-Neck Tumor Proliferation Inhibitor
WO2013056216A1 (en) * 2011-10-14 2013-04-18 New York University Micrornas and methods of using same
WO2015104706A1 (en) * 2014-01-08 2015-07-16 Hadasit Medical Research Services And Development Ltd. Mir-122* as an active micro-rna, compositions comprising the same and uses thereof
WO2017156015A2 (en) * 2016-03-07 2017-09-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Micrornas and methods of their use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
JP2002543214A (en) 1999-05-04 2002-12-17 エクシコン エ／エス L-ribo-LNA analog
AU2002334307A1 (en) 2001-09-04 2003-03-18 Exiqon A/S Novel lna compositions and uses thereof
KR100464261B1 (en) 2002-01-24 2005-01-03 주식회사 파나진 A Novel Monomer For Synthesis of PNA Oligomer And A Process For Producing The Same
KR20030084444A (en) 2002-04-26 2003-11-01 주식회사 파나진 A Novel Monomer For Synthesis of PNA Oligomer And A Process For Producing The Same
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
US7211668B2 (en) 2003-07-28 2007-05-01 Panagene, Inc. PNA monomer and precursor
AU2005222084B2 (en) 2004-03-05 2010-04-22 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of RNAI agents
CN101790385A (en) 2007-07-12 2010-07-28 普罗森那技术公司 Molecules for targeting compounds to various selected organs, tissues or tumor cells
TW200930405A (en) 2007-11-15 2009-07-16 Alcon Res Ltd Low density lipoprotein receptor-mediated siRNA delivery
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
ES2562817T3 (en) 2010-02-24 2016-03-08 Arrowhead Research Corporation Compositions for targeted delivery of ARNip
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
CA2822161C (en) 2010-12-29 2018-05-29 Philipp Hadwiger Small molecule conjugates for intracellular delivery of nucleic acids
EP4043039A1 (en) 2012-01-27 2022-08-17 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120088816A1 (en) * 2009-04-16 2012-04-12 Keio University Head-And-Neck Tumor Proliferation Inhibitor
WO2013056216A1 (en) * 2011-10-14 2013-04-18 New York University Micrornas and methods of using same
WO2015104706A1 (en) * 2014-01-08 2015-07-16 Hadasit Medical Research Services And Development Ltd. Mir-122* as an active micro-rna, compositions comprising the same and uses thereof
WO2017156015A2 (en) * 2016-03-07 2017-09-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Micrornas and methods of their use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HYUN MIN JUNG ET AL: "miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3?", MOLECULAR CANCER, BIOMED CENTRAL, LONDON, GB, vol. 13, no. 1, 8 April 2014 (2014-04-08), pages 80, XP021181989, ISSN: 1476-4598, DOI: 10.1186/1476-4598-13-80 *
JAYAMOHAN SRIDHARAN ET AL: "Dysregulation of miR-375/AEG-1 Axis by Human Papillomavirus 16/18-E6/E7 Promotes Cellular Proliferation, Migration, and Invasion in Cervical Cancer", FRONTIERS IN ONCOLOGY, vol. 9, 9 September 2019 (2019-09-09), CH, pages 1 - 14, XP055878816, ISSN: 2234-943X, DOI: 10.3389/fonc.2019.00847 *
WANG YIHUI ET AL: "MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 444, no. 2, 16 January 2014 (2014-01-16), pages 199 - 204, XP028614852, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2014.01.028 *
WU SHUYING ET AL: "Anti-Condyloma acuminata mechanism of microRNAs-375 modulates HPV in cervical cancer cells via the UBE3A and IGF-1R pathway", ONCOLOGY LETTERS, vol. 16, 18 June 2018 (2018-06-18), GR, pages 3241 - 3247, XP055878890, ISSN: 1792-1074, DOI: 10.3892/ol.2018.8983 *
XU XUENI ET AL: "miR-375-3p suppresses tumorigenesis and partially reverses chemoresistance by targeting YAP1 and SP1 in colorectal cancer cells", AGING, vol. 11, no. 18, 22 September 2019 (2019-09-22), pages 7357 - 7385, XP055878811, ISSN: 1945-4589, DOI: 10.18632/aging.102214 *
YING CHANG ET AL: "miR-375 Inhibits Autophagy and Reduces Viability of Hepatocellular Carcinoma Cells Under Hypoxic Conditions", GASTROENTEROLOGY, ELSEVIER INC, US, vol. 143, no. 1, 9 April 2012 (2012-04-09), pages 177 - 187.e8, XP028497411, ISSN: 0016-5085, [retrieved on 20120412], DOI: 10.1053/J.GASTRO.2012.04.009 *

Also Published As

Publication number Publication date
WO2022056454A2 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2020012797A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use.
MY194058A (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
MX2019001920A (en) Rna for cancer therapy.
MX2020006015A (en) Compositions and methods for inhibiting t cell exhaustion.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2019011530A (en) 11,13-modified saxitoxins for the treatment of pain.
MX2022008523A (en) Glycan-interacting compounds and methods of use.
PH12017502216A1 (en) Nucleic acid-cationic polymer compositions and methods of making and using the same
MX2021005395A (en) Anti-liv1 immune cell cancer therapy.
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
MX2021015337A (en) Multispecific heavy chain antibodies binding to cd22 and cd3.
AU2018271862A1 (en) Combination therapy
MY200161A (en) Bacteria for targeting tumors and treating cancer
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
CA3156667A1 (en) Oligonucleotides with nucleoside analogs
WO2022218941A3 (en) Compositions and methods for inhibiting ketohexokinase (khk)
MX2022016342A (en) Multi-specific antibodies binding to bcma.
MX2022006853A (en) Macrocycles for use in treating disease.
MX2021008834A (en) Methods of treating breast cancer with tucatinib.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
WO2021041324A3 (en) Compositions and methods for the treatment of pathological pain and itch
WO2019190927A3 (en) Splice-switching oligonucleotides and methods of use
MX2017013666A (en) Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21789934

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21789934

Country of ref document: EP

Kind code of ref document: A2